ATYs306Q6fE

81
conditions: a nested case control study. J Cardiovasc Electrophysiol. 2009;20:
401–7.
849. Moss AJ, Zareba W, Benhorin J, Locati EH, Hall WJ, Robinson JL, Schwartz PJ,
Towbin JA, Vincent GM, Lehmann MH. ECG T-wave patterns in genetically
distinct forms of the hereditary long QT syndrome. Circulation. 1995;92:
2929–34.
850. Schwartz PJ, Priori SG, Spazzolini C, Moss AJ, Vincent GM, Napolitano C, Denjoy I,
Guicheney P, Breithardt G, Keating MT, Towbin JA, Beggs AH, Brink P, Wilde AA,
Toivonen L, Zareba W, Robinson JL, Timothy KW, Corfield V, Wattanasirichaigoon
D, Corbett C, Haverkamp W, Schulze-Bahr E, Lehmann MH, Schwartz K, Coumel
P, Bloise R. Genotype-phenotype correlation in the long-QT syndrome: genespecific
triggers for life-threatening arrhythmias. Circulation. 2001;103:89–95.
851. Eckardt L, Kirchhof P, Loh P, Schulze-Bahr E, Johna R, Wichter T, Breithardt G,
Haverkamp W, Borggrefe M. Brugada syndrome and supraventricular
tachyarrhythmias: a novel association? J Cardiovasc Electrophysiol. 2001;12:
680–5.
852. Kaufman ES. Mechanisms and clinical management of inherited channelopathies:
long QT syndrome, Brugada syndrome, catecholaminergic polymorphic
ventricular tachycardia, and short QT syndrome. Heart Rhythm. 2009;6:S51–5.
853. Antzelevitch C, Pollevick GD, Cordeiro JM, Casis O, Sanguinetti MC, Aizawa Y,
Guerchicoff A, Pfeiffer R, Oliva A, Wollnik B, Gelber P, Bonaros EP Jr, Burashnikov
E, Wu Y, Sargent JD, Schickel S, Oberheiden R, Bhatia A, Hsu LF, Haissaguerre M,
Schimpf R, Borggrefe M,Wolpert C. Loss-of-function mutations in the cardiac
calcium channel underlie a new clinical entity characterized by ST-segment
elevation, short QT intervals, and sudden cardiac death. Circulation. 2007;115:
442–9.
854. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S, Viswanathan PC,
Pfahnl AE, Shang LL, Madhusudanan M, Baty CJ, Lagana S, Aleong R, Gutmann R,
Ackerman MJ, McNamara DM, Weiss R, Dudley SC Jr. Mutation in glycerol-3-
phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current
and causes inherited arrhythmias. Circulation. 2007;116:2260–8.
855. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ,
Demolombe S, Probst V, Anselme F, Escande D, Wiesfeld AC, Pfeufer A, Kaab S,
Wichmann HE, Hasdemir C, Aizawa Y, Wilde AA, Roden DM, Bezzina CR. Sodium
channel beta1 subunit mutations associated with Brugada syndrome and cardiac
conduction disease in humans. J Clin Invest.2008;118:2260–8.
856. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M, Menendez TM,
Brugada J, Pollevick GD, Wolpert C, Burashnikov E, Matsuo K, Wu YS, Guerchicoff
A, Bianchi F, Giustetto C, Schimpf R, Brugada P, Antzelevitch C. Sudden death
associated with short-QT syndrome linked to mutations in HERG. Circulation.
2004;109:30–5.
857. Gaita F, Giustetto C, Bianchi F, Wolpert C, Schimpf R, Riccardi R, Grossi S, Richiardi
E, Borggrefe M. Short QT Syndrome: a familial cause of sudden death. Circulation.
2003;108:965–70.
858. Giustetto C, Di Monte F,Wolpert C, Borggrefe M, Schimpf R, Sbragia P, Leone G,
Maury P, Anttonen O, Haissaguerre M, Gaita F. Short QT syndrome: clinical
findings and diagnostic-therapeutic implications. Eur Heart J. 2006;27:2440–7.
859. Bhuiyan ZA, van den Berg MP, van Tintelen JP, Bink-Boelkens MT, Wiesfeld AC,
Alders M, Postma AV, van Langen I, Mannens MM, Wilde AA. Expanding spectrum
of human RYR2-related disease: new electrocardiographic, structural, and
genetic features. Circulation. 2007;116:1569–76.
860. Napolitano C, Priori SG. Diagnosis and treatment of catecholaminergic
polymorphic ventricular tachycardia. Heart Rhythm. 2007;4:675–8.
861. Mohamed U, Napolitano C, Priori SG. Molecular and electrophysiological bases of
catecholaminergic polymorphic ventricular tachycardia. J Cardiovasc
Electrophysiol. 2007;18:791–7.
862. Lee CH, Liu PY, Lin LJ, Chen JH, Tsai LM. Clinical characteristics and outcomes of
hypertrophic cardiomyopathy in Taiwan—a tertiary center experience. Clin
Cardiol. 2007;30:177–82.
863. Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G, Cacace A,
Tocchetti CG, Barbati G, Chiariello M. Determinants of atrial fibrillation
development in patients with hypertrophic cardiomyopathy. Am J Cardiol.
2004;94:895–900.
864. Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA,
Gohman TE, Bongioanni S, Spirito P. Clinical profile of stroke in 900 patients with
hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:301–7.
865. Gollob MH, Seger JJ, Gollob TN, Tapscott T, Gonzales O, Bachinski L, Roberts R.
Novel PRKAG2 mutation responsible for the genetic syndrome of ventricular
preexcitation and conduction system disease with childhood onset and absence
of cardiac hypertrophy. Circulation. 2001;104:3030–3.
866. Postma AV, van de Meerakker JB, Mathijssen IB, Barnett P, Christoffels VM, Ilgun
A, Lam J, Wilde AA, Lekanne Deprez RH, Moorman AF. A gain-of-function TBX5
mutation is associated with atypical Holt-Oram syndrome and paroxysmal atrial
fibrillation. Circ Res. 2008;102:1433–42.
867. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular
cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013;61:
1945–8.
868. Chu AF, Zado E, Marchlinski FE. Atrial arrhythmias in patients with arrhythmogenic
right ventricular cardiomyopathy/dysplasia and ventricular tachycardia. Am J
Cardiol. 2010;106:720–2.
869. Blomstrom-Lundqvist C, Scheinman MM, Aliot EM, Alpert JS, Calkins H, Camm AJ,
Campbell WB, Haines DE, Kuck KH, Lerman BB, Miller DD, Shaeffer CW, Stevenson
WG, Tomaselli GF, Antman EM, Smith SC Jr, Alpert JS, Faxon DP, Fuster V, Gibbons
RJ, Gregoratos G, Hiratzka LF, Hunt SA, Jacobs AK, Russell RO Jr, Priori SG, Blanc JJ,
Budaj A, Burgos EF, Cowie M, Deckers JW, Garcia MA, Klein WW, Lekakis J, Lindahl
B, Mazzotta G, Morais JC, Oto A, Smiseth O, Trappe HJ, European Society of
Cardiology Committee, NASPE-Heart Rhythm Society. ACC/AHA/ESC guidelines
for the management of patients with supraventricular arrhythmias—executive
summary. a report of the American college of cardiology/American heart
association task force on practice guidelines and the European society of
cardiology committee for practice guidelines (writing committee to develop
guidelines for the management of patients with supraventricular arrhythmias)
developed in collaboration with NASPE-Heart Rhythm Society. J Am Coll Cardiol.
2003;42:1493–531.
870. Tischenko A, Fox DJ, Yee R, Krahn AD, Skanes AC, Gula LJ, Klein GJ. When should
we recommend catheter ablation for patients with the Wolff-Parkinson-White
syndrome? Curr Opin Cardiol. 2008;23:32–7.
871. Kibos A, Deharo JC, Adoubi A, Assouan X, Djianeb P. [Clinical and
electrophysiological study of asymptomaticWolff-Parkinson-White syndrome].
Ann Cardiol Angeiol (Paris). 2007;56:237–40.
872. Pappone C, Santinelli V, Manguso F, Augello G, Santinelli O, Vicedomini G,
Gulletta S, Mazzone P, Tortoriello V, Pappone A, Dicandia C, Rosanio S. A
randomized study of prophylactic catheter ablation in asymptomatic patients
with the Wolff-Parkinson-White syndrome. N Engl J Med. 2003;349:1803–11.
873. Boahene KA, Klein GJ, Yee R, Sharma AD, Fujimura O. Termination of acute atrial
fibrillation in the Wolff-Parkinson-White syndrome by procainamide and
propafenone: importance of atrial fibrillatory cycle length. J Am Coll Cardiol.
1990;16:1408–14.
874. O’Nunain S, Garratt CJ, Linker NJ, Gill J, Ward DE, Camm AJ. A comparison of
intravenous propafenone and flecainide in the treatment of tachycardias
associated with the Wolff-Parkinson-White syndrome. Pacing Clin Electrophysiol.
1991;14:2028–34.
875. Manolis AS, Estes NA III. Supraventricular tachycardia. Mechanisms and therapy.
Arch Intern Med. 1987;147:1706–16.
876. Simonian SM, Lotfipour S, Wall C, Langdorf MI. Challenging the superiority of
amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation.
Intern Emerg Med. 2010;5:421–6.
877. Guttmann OP, Rahman MS, O’Mahony C, Anastasakis A, Elliott PM. Atrial
fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy:
systematic review. Heart. 2014;100:465–72.
878. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial
fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation.
2001;104:2517–24.
879. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic
value of non-sustained ventricular tachycardia and the potential role of
amiodarone treatment in hypertrophic cardiomyopathy: assessment in an
unselected nonreferral based patient population. Heart. 1998;79:331–6.
880. Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM, Rea RF,
Shen WK, Powell BD, Ommen SR, Monahan KH, Haroldson JM, Packer DL.
Substrate and procedural predictors of outcomes after catheter ablation for atrial
fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc
Electrophysiol. 2008;19:1009–14.
881. Di Donna P, Olivotto I, Delcre SD, Caponi D, Scaglione M, Nault I, Montefusco A,
Girolami F, Cecchi F, Haissaguerre M, Gaita F. Efficacy of catheter ablation for
atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial
remodelling, and disease progression. Europace. 2010;12:347–55.
882. Gaita F, Di Donna P, Olivotto I, Scaglione M, Ferrero I, Montefusco A, Caponi D,
Conte MR, Nistri S, Cecchi F. Usefulness and safety of transcatheter ablation of
atrial fibrillation in patients with hypertrophic cardiomyopathy. Am J Cardiol.
2007;99:1575–81.
883. Kilicaslan F, Verma A, Saad E, Themistoclakis S, Bonso A, Raviele A, Bozbas H,
Andrews MW, Beheiry S, Hao S, Cummings JE, Marrouche NF, Lakkireddy D,
Wazni O, Yamaji H, Saenz LC, SalibaW, Schweikert RA, Natale A. Efficacy of
catheter ablation of atrial fibrillation in patients with hypertrophic obstructive
cardiomyopathy. Heart Rhythm. 2006;3:275–80.
884. McCready JW, Smedley T, Lambiase PD, Ahsan SY, Segal OR, Rowland E, Lowe MD,
Chow AW. Predictors of recurrence following radiofrequency ablation for
persistent atrial fibrillation. Europace. 2011;13:355–61.
885. Ritchie MD, Rowan S, Kucera G, Stubblefield T, Blair M, Carter S, Roden DM,
Darbar D. Chromosome 4q25 variants are genetic modifiers of rare ion channel
mutations associated with familial atrial fibrillation. J Am Coll Cardiol.
2012;60:1173–81.
886. Mann SA, Otway R, Guo G, Soka M, Karlsdotter L, Trivedi G, Ohanian M, Zodgekar
P, Smith RA, Wouters MA, Subbiah R, Walker B, Kuchar D, Sanders P, Griffiths L,
Vandenberg JI, Fatkin D. Epistatic effects of potassium channel variation on
cardiac repolarization and atrial fibrillation risk. J Am Coll Cardiol. 2012;59:
1017–25.
887. Giustetto C, Cerrato N, Gribaudo E, Scrocco C, Castagno D, Richiardi E, Giachino D,
Bianchi F, Barbonaglia L, Ferraro A. Atrial fibrillation in a large population with
Brugada electrocardiographic pattern: prevalence, management, and correlation
with prognosis. Heart Rhythm. 2014;11:259–65.
888. Darbar D, Kannankeril PJ, Donahue BS, Kucera G, Stubblefield T, Haines JL, George
AL Jr, Roden DM. Cardiac sodium channel (SCN5A) variants associated with atrial
fibrillation. Circulation. 2008;117:1927–35.
889. Olson TM, Michels VV, Ballew JD, Reyna SP, Karst ML, Herron KJ, Horton SC,
Rodeheffer RJ, Anderson JL. Sodium channel mutations and susceptibility to heart
failure and atrial fibrillation. JAMA. 2005;293:447–54.
890. Ellinor PT, Moore RK, Patton KK, Ruskin JN, Pollak MR, Macrae CA. Mutations in
the long QT gene, KCNQ1, are an uncommon cause of atrial fibrillation. Heart.
2004;90:1487–8.
891. Priori SG, Wilde AA, Horie M, Cho Y, Behr ER, Berul C, Blom N, Brugada J, Chiang
CE, Huikuri H, Kannankeril P, Krahn A, Leenhardt A, Moss A, Schwartz PJ, Shimizu